Surging ahead with a dramatic growth in sales of its products, Indian Medicines Pharmaceutical Corporation Limited (IMPCL), the public sector manufacturing unit of the Ministry of AYUSH has recorded a turnover of Rs 164.33 Crore (tentative figure) for the financial year 2020-21. This is the highest number achieved in the company’s history and an all-time high profit of approximately Rs 12 crore is reported for the year. In the previous year 2019-20 best revenue figures of the company was Rs 97 Crore. This growth is reflective of the fast-growing adoption of AYUSH products and services by the public in the wake of COVID-19 pandemic.
Adding another feather in IMPCL’s cap, the Central Drugs Standards Control organisation (CDSCO) recently recommended its 18 Ayurvedic products for WHO-GMP/COPP certification subject to certain observations in March 2021. ‘World Health Organization, Good Manufacturing Practices / Certificate of Pharmaceutical Product (WHO-GMP/CoPP)’ certification is given to companies after conducting an inspection. This certification is an endorsement of the quality of IMPCL’s products. It will help IMPCL to commence export operation of quality medicines at a global level.
IMPCL is one of the most trusted manufacturers of AYUSH medicines in the country and is known for the authenticity of its formulations. During the COVID-19 pandemic, it was able to cater the needs of the country in the shortest time, probably the first company in the country to provide Immuno boosting medicines as AurakshaImmuno Boosting Kit. At Rs 350, it is one of the lowest-priced such kits and is also available on Amazon. Nearly 2 lakh such kits have been sold in the last two months.
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum. It has contributed towards research and development activities and 25 new proprietary Ayurvedic medicines as per the Essential Drug List (EDL).
Every Government institution doing business with IMPCL has praised the company for providing steady support to various health programmes and ensuring an unbroken supply of products during the e COVID-19 pandemic.